Fredun Pharma's guidance leap raises credibility questions
Mobility growth guidance nearly doubled between calls; two product launches slipped months
The numbers
- FY26 revenue ₹639 cr, up 40% YoY, with EBITDA margin at 14.8% as new-age businesses scale.
- Mobility division earned ₹29-30 cr in FY26; management targets ₹100 cr run rate in 2.5 years.
- PAT margin target of 10-12% implies a significant improvement from trailing ROE of 11.7%.
- Stock trades at 38.9x P/E; earnings acceleration needed to justify the multiple.
Management's story
- Guides 25-30% revenue growth for FY27, preferring to under-promise and over-deliver.
- Claims mobility is now growing at a 55-60% CAGR, nearly double the 25-30% rate stated in February.
- Plans to launch first- and second-in-India products in hormonal therapies and anti-aging.
- Pet care platform Wagr slipped from February to July; Mobilitix brand from April to July.
- Targets new-age businesses at 50% of revenue in a few years and 70% in 5-6 years.
“We have had an amazing response... growing at almost a 55% to 60% CAGR.”
— Fredun Pharma management, Jun 2026 call
Where they diverge
The near-doubling of mobility growth guidance between the February and June calls, from 25-30% YoY to 55-60% CAGR, came with no new contracts or data. Combined with repeated launch delays for Mobilitix and Wagr, management's narrative of accelerating execution clashes with the slipping timelines. The company's stated preference for under-promising makes the unexplained guidance jump hard to reconcile with the numbers.
The full read
Fredun Pharmaceuticals delivered a strong FY26: revenue up 40% to ₹639 cr, EBITDA margin reaching 14.8%. But the earnings call tells a different story on forward guidance. Mobility growth guidance nearly doubled from February's 25-30% YoY to a 55-60% CAGR in June, with no new data or contracts to explain the jump. Two strategic product launches slipped: Mobilitix from April to July, Wagr from February to July. Management's guidance now moves faster than the business it describes. The 25-30% FY27 revenue target aligns with trailing growth, but the mobility step-up and repeated delays erode credibility. The PAT margin target of 10-12% depends on the mix shift to higher-margin consumer and mobility verticals. If execution holds, the 38.9x P/E could be justified. But the gap between narrative and numbers is growing. Investors need the July launches to confirm the trajectory.
What we're watching
- Mobilitix and Wagr platform launches in July 2026 as newly committed deadlines.
- Q1 FY27 results to see if mobility growth actually matches the new 55-60% CAGR.
- Raw material and petroleum input cost trends that management flagged as a near-term risk.
- Gross margin trajectory as new-age businesses with 45-55% margins scale vs. vintage pharma.